Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib as Prophylaxis for Chronic GVHD in Allo-HCT Patients
NCT06271616Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Mayo Clinic. Started Dec 2024; status: terminated.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06271616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271616.